Recent Updates
Recently added Catalysts
KPTI

Karyopharm to Present at the 15th Annual Needham Healthcare Conference

Key Takeaway: NEWTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming 15th Annual Ne

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+105%
120-day peak, hindsight
Typical move
15.1%
average across 5 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
Selinexor
Phase 2 · Acute Myeloid Leukemia (AML)

Full Press Release Details

NEWTON, Mass., April 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming 15th Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 8:40 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
Last updated: Apr 5, 2016